Abstract
The TP53 tumor suppressor gene coding for a nuclear phosphoprotein involved in cellular stress responses is the most frequently mutated gene in human cancers described so far (1–4). Mutations are found throughout the gene but most frequently within the highly conserved middle region (exons 5–8) that encodes for the DNA-binding central region of the gene critical for the major function of TP53 protein as a transcriptional activator (5). The mutation spectrum of the TP53 gene varies from one tumor type to another with typical hot-spot codons for mutations (2,6). For instance, codons 157, 248, and 273 are frequently mutated in cigarette smoking-associated lung cancer, whereas mutations in codon 175 are rare. This codon, on the other hand, is often mutated in breast and colon cancer. In some cases, typical mutations can be linked with environmental exposures, such as CC→TT double mutation with UV radiation (7) and codon 249 AGG→AGT mutation with aflatoxin B1 and hepatitis B virus (8). These findings, in connection with the fact that one of the main functions of TP53 protein is putatively the protection of the genome (9,10) implicate the mutations of the TP53 gene in environmentally induced carcino-genesis in humans and the possible use of TP53-related markers in molecular epidemiology (11–13)
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. (1991) p53 mutations in human cancers. Science 253, 49–53.
Greenblatt, M. S., Bennett, W. P., Hollstein, M., and Harris, C. C. (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54, 4855–4878.
Hainaut, P., Soussi, T., Shomer, B., Hollstein, M., Greenblatt, M., Hovig, E., Harris, C. C., and Montesano, R. (1997) Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. Nucleic Acids Res. 25, 151–157.
Hussain, S. P. and Harris, C. C. (1998) Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor suppressor genes. Cancer Res. 58, 4023–4037.
Gottlieb, T. M. and Oren, M. (1996) p53 in growth control and neoplasia. Biochim. Biophys. Acta 1287, 77–102.
Hernandez-Boussard, T. M. and Hainaut, P. (1998) A specific spectrum of p53 mutations in lung cancer from smokers: review of mutations compiled in the I ARC p53 database. Environ. Health Perspect. 106, 385–391.
Brash, D. E., Rudolph, J. A., Simon, J. A., Lin, A., McKenna, G. J., Baden, H. P., Halperin, A. J., and Ponten, J. (1991) A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc. Natl. Acad. Sci. USA 88, 10,124–10,128.
Ozturk, M. (1991) p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet 338, 1356–1359.
Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W. (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51, 6304–6311.
Lane, D. P. (1992) p53, guardian of the genome. Nature 358, 15,16.
Harris, C. C. (1996) The 1995 Walter Hubert Lecture—molecular epidemiology of human cancer: insights from the mutational analysis of the p53 tumoursuppressor gene. Br. J. Cancer 73, 261–269.
Perera, F. P., Whyatt, R. M., Jedrychowski, W., Rauh, V., Manchester, D., Santella, R. M., and Ottman, R. (1998) Recent developments in molecular epidemiology: a study of the effects of environmental poly cyclic aromatic hydrocarbons on birth outcomes in Poland. Am. J. Epidemiol. 147, 309–314.
Hainaut, P. and Vähäkangas, K. (1997) p53 as a sensor of carcinogenic exposures: mechanisms of p53 protein induction and lessons from p53 gene mutations. Pathologie-Biologie 45, 833–844.
Bergh, J., Norberg, T., Sjögren, S., Lindgren, A., and Holmberg, L. (1995) Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat. Med. 1, 1029–1034.
Borresen, A.-L., Anderson, T. I., Eyfjörd, J. E., Cornelis, R. S., Thorlacius, S., Borg, 0, A., Johansson, U., Theillet, C., Scherneck, S., Hartman, S., Cornelisse, C. J., Hovig, E., and Devilee, P. (1995) TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosomes Cancer 14, 71–75.
Valgardsdottir, R., Tryggvadottir, L., Steinarsdottir, M., Olafsdottir, K., Jonasdottir, S., Jonasson, J. G., Ögmundsdottir, H. M., and Eyfjörd, J. E. (1997) Genomic instability and poor prognosis associated with abnormal TP53 in breast carcinomas: molecular and immunohistochemical analysis. APMIS 105, 121–130.
Soini, Y., Turpeenniemi-Hujanen, T., Kamel, D., Autio-Harmainen, H., Risteli, J., Risteli, L., Nuorva, K., Pääkkö, P., and Vähäkangas, K. (1993) p53 Immunohistochemistry in transitional cell carcinoma and dysplasia of the urinary bladder correlates with disease progression. Br. J. Cancer 68, 1029–1035.
Uchida, T., Wada, C., Ishida, H., Wang, C., Egawa, S., Yokoyama, E., Kameya, T., and Koshiba, K. (1999) p53 mutations and prognosis in bladder tumors. J. Urol. 153, 1097–1104.
Peller, S., Halperin, R., Schneider, D., Kopilova, Y., and Rotter, V. (1999) Polymorphisms of the p53 gene in women with ovarian or endometrial carcinoma. Oncol. Rep. 6, 193–197.
Wang, Y. C., Chen, C. Y., Chen, S. K., Chang, Y. Y., and Lin, P. (1999) p53 codon 72 polymorphism in Taiwanese lung cancer patients: association with lung cancer susceptibility and prognosis. Clin. Cancer Res. 5, 129–134.
Murata, M., Tagawa, M., Kimura, H., Kakisawa, K., Shirasawa, H., and Fujisawa, T. (1998) Correlation of the mutation of p53 gene and the polymorphism at codon 72 in smoking-related non-small cell lung cancer patients. Int. J. Oncol. 12, 577–581.
Murata, M., Tagawa, M., Kimura, M., Kimura, H., Watanabe, S., and Saisho, H. (1996) Analysis of a germ line polymorphism of the p53 gene in lung cancer patients: discrete results with smoking history. Carcinogenesis 17, 261–264.
Storey, A., Thomas, M., Kalita, A., Harwood, C., Gardiol, D., Mantovani, F., Breuer, J., Leigh, I. M., Matlashewski, G., and Banks, L. (1998) Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 393, 229–234.
Thomas, M., Kalita, A., Labreque, S., Pim, D., Banks, L., and Matlashewski, G. (1999) Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol. CellBiol. 19, 1092–1100.
Storey, A., Thomas, M., Kalita, A., Harwood, C., Gardiol, D., Mantovani, F., Breuer, J., Leigh, I. M., Matlashewski, G., and Banks, L. (1998) p53 polymorphism and risk of cervical cancer. Nature 396, 532.
Rosenthal, A. N., Ryan, A., Al-Jehani, R. M., Storey, A., Harwood, C. A., and Jacobs, I. J. (1998) p53 codon 72 polymorphism and risk of cervical cancer in UK. Lancet 352, 871,872.
Helland, A., Langerod, A., Johnsen, H., Olsen, A. O., Skovlund, E., and Borresen-Dale, A.-L. (1998) p53 polymorphism and risk of cervical cancer. Nature 396, 530,531.
Josefsson, A. M., Magnusson, P. K. E., Ylitalo, N., Quarforth-Tubbin, P., Ponten, J., Adami, H. O., and Gyllensten, U. B. (1998) p53 polymorphism and risk of cervical cancer. Nature 396, 531.
Hildesheim, A., Schiffman, M., Brinton, L. A., Fraumeni, J. F.Jr., Herrero, R., Bratti, M. C., Schwartz, P., Mortel, R., Barnes, W., Greenberg, M., McGowan, L., Scott, D. R., Martin, M., Herrera, J. E., and Carrington, M. (1998) p53 polymorphism and risk of cervical cancer. Nature 396, 531,532.
Minaguchi, T., Kanamori, Y., Matsushima, M., Yoshikawa, H., Taketani, Y., and Nakamura, Y. (1998) No evidence of correlation between polymorphism at codon 72 of p53 and risk of cervical cancer in Japanese patients with human papillomavirus 16/18 infection. Cancer Res. 58, 4585,4586.
Orita, M., Iwahana, H., Kanazawa, H., Hayashi, K., and Sekiya, T. (1989) Detection of polymorphisms of human DNA by gel electrophoresis as single strand conformation polymorphisms. Proc. Natl. Acad. Sci. USA 86, 2766–2770.
Chaubert, P., Beautista, D., and Benhattar J. (1993) An improved method for rapid screening of DNA mutations by nonradioactive single-strand conformation polymorphism procedure. BioTechniques 15, 586.
Cheng, J. and Haas, M. (1992) Sensitivity of detection of heterozygous point mutations in p53 cDNAs by direct PCR sequencing. PCR Methods Appl. 1, 199–201.
Wu, J. K., Ye, Z., and Darras, B. T. (1993) Sensitivity of single-strand conformation polymorphism (SSCP) analysis in detecting p53 point mutations in tumors with mixed cell populations. Am. J. Hum. Genet. 52, 1273–1275.
Mohabeer, A. J., Hiti, A. L., and Martin, W. J. (1991) Non-radioactive singlestrand conformation polymorphism (SSCP) using the Pharmacia’ PhastSystem’. Nucleic Acid Res. 19, 3154.
Neubauer, A., Brendel, C., Vogel, D., Schmidt, C. A., Heide, I., and Huhn, D. (1993) Detection of p53 mutations using nonradioactive SSCP analysis: p53 is not frequently mutated in myelodysplastic syndromes (MDS). Ann. Hematol. 67, 223–226.
Bosari, S., Marchetti, A., Buttitta, F., Graziani, D., Borsani, G., Loda, M., Bevilacqua, G., and Coggi, G. (1995) Detection of p53 mutations by single-strand conformation polymorphisms (SSCP) gel electrophoresis. Diagn. Mol. Pathol. 4, 249–255.
Kurvinen, K., Hietanen, S., Syrjänen, K., and Syrjänen, S. (1995) Rapid and effective detection of mutations in the p53 gene using nonradioactive single-strand conformation polymorphism (SSCP) technique applied on PhastSystem™. J. Virol. Methods 51, 43–54.
Welsh, J.A., Castrén, K., and Vähäkangas, K. (1997) Single-strand conformation polymorphism analysis to detect p53 mutations: characterization and development of controls. Clin. Chem. 43, 2251–2255.
Lehman, T. A., Bennett, W. P., Metcalf, R. A., Welsh, J. A., Ecker, J., Modali, R. V., Ullrich, S., Romano, J. W., Appella, E., Testa, J. R., Gerwin, B. I., Vogelstein, B., and Harris, C. C. (1991) p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines. Cancer Res. 51, 4090–4096.
Castrén, K., Vähäkangas, K., Heikkinen, E., and Ranki, A. (1998) Absence of p53 mutations in benign and pre-malignant male genital lesions with overexpressed p53 protein. Int. J. Cancer 77, 674–678.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Humana Press Inc.
About this protocol
Cite this protocol
Vähäkangas, K.H., Castrén, K., Welsh, J.A. (2001). Single-Strand Conformation Polymorphism Analysis of Mutations in Exons 4-8 of the TP53 Gene. In: Killeen, A.A. (eds) Molecular Pathology Protocols. Methods in Molecular Medicine™, vol 49. Humana Press. https://doi.org/10.1385/1-59259-081-0:15
Download citation
DOI: https://doi.org/10.1385/1-59259-081-0:15
Publisher Name: Humana Press
Print ISBN: 978-0-89603-681-9
Online ISBN: 978-1-59259-081-0
eBook Packages: Springer Protocols